SUMMARY, EXPLANATION AND LIMITATIONS:
CD30 is a trans-membrane cytokine receptor belonging to the family of tumour necrosis factors (TNF). The matured protein has a molecular weight of 120 kDa and arises from a 90 kDa precursor protein. CD30 is expressed by Hodgkin- and Reed-Sternberg-cells (H-RS), anaplastic large cell (ALCL) and activated B- and Tcells. Staining of CD30 is useful for identification of ALCL and for more differentiated characterisation of Hodgkin’s disease. In non-lymphoid tissues CD30 can be detected in embryonal carcinomas, seminomas, mesotheliomas and in decidua cells (Dürkop et al.).
Immunogen: Co cell line of patient with Hodgkin lymphoma.
Staining pattern: Cell membrane and granular cytoplasmatic.
Positive control: Tissue sample from Hodgkin’s lymphoma.
This antibody is designed for the specific localization of human CD30 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
In neoplasms CD30 antigen is expressed in some anaplastic tumors, as is the case of mono-bi-cells, multinucleated Hodgkin’s disease and large cell anaplastic lymphoma most large cell, one third of which lack the CD45 marker and immunostaining under certain conditions, in some myeloid and lymphoid leukemias, normal plasma cells, plasmacytoma and multiple myeloma. The CD30 antigen is also expressed in some hematopoietic neoplasms such as embryonal carcinomas and rarely in poorly differentiated tumors of epithelial origin or melanin.